There was a 22.4% reduction in the risk of death with quizartinib compared to standard chemotherapy alone (HR = 0.776; 2-sided p = 0.032) in patients with newly diagnosed FLT3-ITD positive AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.